Keros Therapeutics adopts poison pill and launches strategic review including potential sale

Keros Therapeutics, Inc.

Board formed Strategic Committee to evaluate strategic alternatives including sale or business combination.
Adopted limited-duration rights plan (10% threshold, 15% for passive institutional) expiring April 9, 2026.
Rights plan triggered by an individual investor that disclosed 11.2% ownership as of April 6, 2025.
Dividend of one right per common share for stockholders of record on April 24, 2025.
Goldman Sachs & Co. LLC engaged as financial advisor; Cooley LLP as legal counsel.

item 1.01 item 3.03 item 5.03 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.